Jefferies Group LLC set a €92.00 ($108.24) target price on shares of Sanofi SA and gave the stock a "neutral" rating in a report on Friday, May 12th. Finally, Barclays PLC set a €18.50 ($21.76) price target on shares of Vivendi SA and gave the stock a sell rating in a research note on Friday, May 12th.
Sanofi SA (EPA:SAN) received a €82.00 ($96.47) price target from stock analysts at Goldman Sachs Group, Inc. The average twelve-month price target among brokerages that have issued ratings on the stock in the previous year is €50.03 ($58.86). Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. The company has an average rating of Hold and a consensus price target of €20.27 ($23.85). Barclays PLC set a €57.00 ($67.06) price objective on Total SA and gave the company a "buy" rating in a research report on Friday, July 28th. Finally, Barclays PLC set a €84.00 ($98.82) price objective on shares of Vinci SA and gave the company a "buy" rating in a report on Monday, July 31st. Morgan Stanley set a €73.00 ($85.88) price objective on Vinci SA and gave the stock a neutral rating in a research note on Wednesday, April 5th.
Shares of Sanofi SA (SAN) traded down 0.04% during trading on Tuesday, hitting €80.77. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is €50.03 ($58.86).
SBI standalone net profit at Rs 2005 cr, NPA shoots up
SBI expected these bad loans, which are under its national banking portfolio, would see a "pull back" to the standard category. Net interest income fell 3.5 per cent to Rs 17,606 crore on like-to-like basis which was due to lower lending rates.
ILLEGAL ACTIVITY WARNING: "Vinci SA (DG) PT Set at €96.00 by Goldman Sachs Group, Inc".
TRADEMARK VIOLATION NOTICE: This article was posted by Stock Observer and is the property of of Stock Observer. Sanofi SA has a 52 week low of €62.50 and a 52 week high of €92.97. The firm's 50-day moving average price is €76.44 and its 200-day moving average price is €74.20. The stock has a market cap of €42.72 billion and a P/E ratio of 16.50. If you are reading this report on another site, it was copied illegally and republished in violation of United States & worldwide copyright and trademark law. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.